PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33193892-8	2020	Moreover, multivariate analysis indicated that BM status (P=0.015), local therapy for BM (P=0.013) and subsequent treatment of Osimertinib (P=0.008) impact significantly on OS.	osimertinib	127-138	Moloney sarcoma oncogene	Mus musculus	173-175	
34457028-5	2021	Forty-four osimertinib-treated patients had an improved mOS of 13.15 (95% CI: 5.74-20.57) and a median progression-free survival (PFS) of 9.50 months (95% CI: 6.77-12.23) when compared with patients treated with first- or second-generation EGFR-TKI (mOS = 3.00 months (95% CI: 1.32-4.68) and median PFS = 1.50 months (95% CI: 0.00-3.14)).	osimertinib	11-22	Moloney sarcoma oncogene	Mus musculus	56-59	
34457028-6	2021	In the osimertinib group, mOS values for CSF with and without T790M mutation were 22.15 months (95% CI: 9.44-34.87) and 13.39 months (95% CI: 7.01-19.76), respectively, with no statistical differences.	osimertinib	7-18	Moloney sarcoma oncogene	Mus musculus	26-29	
32652216-2	2020	Current study explored whether treatment with osimertinib leads to improved overall survival (OS) for EGFR-mutated NSCLC patients with leptomeningeal metastases (LM) compared with those not treated with osimertinib.	osimertinib	46-57	Moloney sarcoma oncogene	Mus musculus	94-96	
32652216-8	2020	However, patients treated with osimertinib showed a superior OS of 17.0 months (95% CI, 15.13-18.94) compared with those not treated with osimertinib who showed a mOS 5.5 months (95% CI 4.34-6.63) regardless of T790M mutational status (HR 0.36; 95% CI 0.28-0.47, P <0.001).	osimertinib	31-42	Moloney sarcoma oncogene	Mus musculus	61-63